Figure 3.
e-sEVs increase capillary density and protect muscle from ischemic damage. (A) Representative hematoxylin-eosin images of gastrocnemius muscles of non-ischemic (Normal hind limb) and ischemic hind limb of Vehicle, e-sEVs and i-sEVs treated animals (Original Magnification: ×200; scale bar: 50 µm), (upper panels). Representative immunofluorescence images (confocal microscopy) of capillary density staining. An anti-CD31 mAb was used to analyze gastrocnemius muscles of non-ischemic (Normal hind limb) and ischemic hind limbs as indicated (Original Magnification: ×400; scale bar: 25 µm) (lower panels). (B) Quantitative analysis of muscle damage areas in hematoxilin-eosin stained gastrocnemius muscles of normal and ischemic hind limbs at day 7 after surgery. e-sEVs significantly reduce muscle damage compared to Vehicle. Data are expressed as mean ± SEM; *p < 0.05 e-sEVs vs Vehicle, (One-way ANOVA - Newman-Keuls Multiple Comparison Test), (left panel) (n = 10). Quantitative analysis of capillary density of normal and ischemic hind limbs at day 7 after surgery indicates that e-sEVs significantly increase capillary density compared to Vehicle. Data are expressed as mean ± SEM; *p < 0.05, e-sEVs vs Vehicle, (One-Way ANOVA - Newman-Keuls Multiple Comparison Test), (right panel).